Base de dados : MEDLINE
Pesquisa : D04.210.500.745.432.719.526 [Categoria DeCS]
Referências encontradas : 653 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 66 ir para página                         

  1 / 653 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28802371
[Au] Autor:Ocak E; Kocaoz D; Acar B
[Ad] Endereço:Department of Otorhinolaryngology, Kecioren Research and Training Hospital, Ankara, Turkey.
[Ti] Título:How can we improve medical adherence to intranasal corticosteroids in children?
[So] Source:Int J Pediatr Otorhinolaryngol;100:194-197, 2017 Sep.
[Is] ISSN:1872-8464
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate the factors which may be related to nonadherence to intranasal corticosteroids (ICS) in the treatment of allergic rhinitis (AR) in children. METHODS: A prospective study was conducted on children with AR diagnosis in a tertiary referral hospital. All participants were provided with mometasone furoate nasal sprays for 30 days after the diagnosis. Caregivers were called back when the therapy was over and completed a questionnaire about the factors that may influence the adherence to the treatment. Afterwards each caregiver completed the Turkish language validated Morisky Medical Adherence Scale (MMAS-8) form. Each factor was evaluated according to MMAS-8 score and all variables were analyzed statistically. RESULTS: A total number of 76 children with a mean age of 7.82 years were included in the study. The mean overall MMAS-8 score was 2.80. There was only one factor significantly related to low adherence; the number of dependent children to the caregiver (p = 0.011). Besides this 71.51% of the answers to MMAS-8 scale were compatible with good adherence. CONCLUSION: The clinician must consider the factors which may lead to non-adherence while setting up a treatment plan. The demographic and sociocultural factors must be taken into consideration and treatment schedule should be made in respect of daily activities of the children. Moreover the father can be involved in the therapy plan and back up the mother as they are usually the responsible parent for children's medical therapy.
[Mh] Termos MeSH primário: Antialérgicos/administração & dosagem
Glucocorticoides/administração & dosagem
Adesão à Medicação
Furoato de Mometasona/administração & dosagem
Rinite Alérgica/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Intranasal
Criança
Feminino
Seres Humanos
Masculino
Sprays Nasais
Estudos Prospectivos
Inquéritos e Questionários
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Allergic Agents); 0 (Glucocorticoids); 0 (Nasal Sprays); 04201GDN4R (Mometasone Furoate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170907
[Lr] Data última revisão:
170907
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170814
[St] Status:MEDLINE


  2 / 653 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28514369
[Au] Autor:Shakhova EG
[Ad] Endereço:Volgograd State Medical University, Ministry of Health of the Russian Federation, Volgograd, Russian Federation.
[Ti] Título:[The role of topical glucocorticoids in the treatment of rhinosinusitis].
[Ti] Título:Mesto topicheskikh gliukokortikosteroidov v lechenii rinosinusita..
[So] Source:Vestn Otorinolaringol;82(2):70-73, 2017.
[Is] ISSN:0042-4668
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:The guidelines of the European position paper on rhinosinusitis and nasal polyps (EPOS, 2012) ascribe the highest strength and the most comprehensive evidence-based significance to the application of intranasal glucocorticosteroids (inGCS) as the first-line therapy for the patients presenting with acute and polypous rhinosinusitis; moreover they are recommended as the medications of choice for the treatment of chronic rhinosinusitis in the absence of polyps. The author presents the data concerning the mechanism of action, clinical effectiveness, and safety of inGCS used for the treatment of acute, recurrent, and chronic rhinosinusitis. It is shown that mometason furoate produces the favourable therapeutic effect and is possessed of beneficial pharmacodynamic and pharmacokinetic properties in the cases of its topical application. The comparative randomized clinical study (RCS) of the new preparation of mometason furoate in the form of the intranasal spray (manufactured by 'Teva' Ltd.) registered in the Russian Federation in 2015 has demonstrated that it can be considered as a therapeutic equivalent to nasonex.
[Mh] Termos MeSH primário: Furoato de Mometasona
Rinite
Sinusite
[Mh] Termos MeSH secundário: Administração Intranasal
Glucocorticoides/administração & dosagem
Glucocorticoides/farmacocinética
Seres Humanos
Furoato de Mometasona/administração & dosagem
Furoato de Mometasona/farmacocinética
Mucosa Nasal/efeitos dos fármacos
Gravidade do Paciente
Guias de Prática Clínica como Assunto
Ensaios Clínicos Controlados Aleatórios como Assunto
Rinite/diagnóstico
Rinite/tratamento farmacológico
Federação Russa
Sinusite/diagnóstico
Sinusite/tratamento farmacológico
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glucocorticoids); 04201GDN4R (Mometasone Furoate)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170713
[Lr] Data última revisão:
170713
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170518
[St] Status:MEDLINE
[do] DOI:10.17116/otorino201782270-73


  3 / 653 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28337893
[Au] Autor:Gelardi M; De Luca C; Taliente S; Fiorella ML; Quaranta N; Russo C; Ciofalo A; Macchi A; Mancini M; Rosso P; Seccia V; Guagnini F; Ciprandi G
[Ad] Endereço:Otolaryngology, Department of Basic Medical Science, Neuroscience and Sensory Organs, University of Bari “Aldo Moro”, Bari, Italy.
[Ti] Título:Adjuvant treatment with a symbiotic in patients with inflammatory non-allergic rhinitis.
[So] Source:J Biol Regul Homeost Agents;31(1):201-206, 2017 Jan-Mar.
[Is] ISSN:0393-974X
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:Inflammatory non-allergic rhinitis (INAR) is characterized by the presence of an inflammatory infiltrate and a non-IgE-mediated pathogenesis. This retrospective, controlled, multicentre study investigated whether a symbiotic, containing Lactobacillus acidophilus NCFM, Bifidobacterium lactis, and fructo-oligosaccharides (Pollagen®, Allergy Therapeutics, Italy), prescribed as adjunctive therapy to a standard pharmacological treatment, was able to reduce symptom severity, endoscopic features, and nasal cytology in 93 patients (49 males and 44 females, mean age 36.3±7.1 years) with INAR. The patients were treated with nasal corticosteroid, oral antihistamine, and isotonic saline. At randomization, 52 patients were treated also with symbiotic as adjunctive therapy, whereas the remaining 41 patients served as controls. Treatment lasted for 4 weeks. Patients were visited at baseline, after treatment, and after 4-week follow-up. Adjunctive symbiotic treatment significantly reduced the percentages of patients with symptoms and endoscopic signs, and diminished inflammatory cells. In conclusion, the present study demonstrates that a symbiotic was able, as adjuvant treatment, to significantly improve symptoms, endoscopic feature, and cytology in patients with INAR, and its effect may be long lasting.
[Mh] Termos MeSH primário: Adjuvantes Imunológicos/administração & dosagem
Adjuvantes Farmacêuticos/administração & dosagem
Bifidobacterium animalis/imunologia
Lactobacillus acidophilus/imunologia
Probióticos/administração & dosagem
Rinite/terapia
[Mh] Termos MeSH secundário: Administração Intranasal
Administração Oral
Corticosteroides/uso terapêutico
Adulto
Terapia Combinada/métodos
Ciproeptadina/análogos & derivados
Ciproeptadina/uso terapêutico
Feminino
Antagonistas dos Receptores Histamínicos/uso terapêutico
Seres Humanos
Masculino
Furoato de Mometasona/uso terapêutico
Prebióticos/administração & dosagem
Estudos Retrospectivos
Rinite/imunologia
Rinite/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Adjuvants, Pharmaceutic); 0 (Adrenal Cortex Hormones); 0 (Histamine Antagonists); 0 (Prebiotics); 04201GDN4R (Mometasone Furoate); 2AE8M83G3E (rupatadine); 2YHB6175DO (Cyproheptadine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170601
[Lr] Data última revisão:
170601
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170325
[St] Status:MEDLINE


  4 / 653 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28329523
[Au] Autor:An I; Demir V; Ibiloglu I; Akdeniz S
[Ad] Endereço:Department of Dermatology, Dicle University Faculty of Medicine, Diyarbakir, Turkey. is_an89@hotmail.com.
[Ti] Título:Lichen planus secondary to rabies vaccination.
[So] Source:Dermatol Online J;23(3), 2017 Mar 15.
[Is] ISSN:1087-2108
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Lichen planus (LP) is a papulosquamous disease withdistinctive clinical manifestations. The etiology of LPremains unknown. Recently, numerous cases of LPdeveloping after hepatitis B, influenza, and combinedDTaP-IPV-MMR vaccine have been described. In thisreport, we present the second case of LP after rabiesvaccination.
[Mh] Termos MeSH primário: Líquen Plano/induzido quimicamente
Vacinas Antirrábicas/efeitos adversos
Raiva/prevenção & controle
[Mh] Termos MeSH secundário: Administração Cutânea
Adulto
Fármacos Dermatológicos/uso terapêutico
Feminino
Seres Humanos
Líquen Plano/diagnóstico
Líquen Plano/tratamento farmacológico
Líquen Plano/patologia
Furoato de Mometasona/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dermatologic Agents); 0 (Rabies Vaccines); 04201GDN4R (Mometasone Furoate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170323
[St] Status:MEDLINE


  5 / 653 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28277845
[Au] Autor:Krishna R; Horowitz A; Larson P; Bolognese J; Marcantonio EE
[Ad] Endereço:a Merck Research Laboratories, Merck & Co, Inc , Kenilworth , NJ , USA.
[Ti] Título:Topical safety and vasoconstrictive assay-based bioequivalence of a new reformulated mometasone cream.
[So] Source:Drug Dev Ind Pharm;43(7):1173-1177, 2017 Jul.
[Is] ISSN:1520-5762
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: A new improved mometasone furoate (Elocon™) cream with an emulsification system that produces a stable emulsion has been developed. In order to register the product in various markets, it was essential to ensure the cream was topically well tolerated and that it was bioequivalent to the reference product. METHODS: Phase I clinical studies were performed to assess the local safety and tolerability upon multiple dosing of this new cream as well as to assess the single-dose bioequivalence relative to the marketed product. Bioequivalence was assessed using a vasoconstrictive assay (VCA) after a dose-duration pilot study was completed with the marketed Elocon cream. KEY FINDINGS: The new mometasone cream and its vehicle were nonirritating in healthy subjects during 21-day patch application (MCII <0.025). The positive control was moderately irritating in the same study. The pivotal VCA study enrolled 162 subjects with 105 detectors included in the analysis of bioequivalence. In the 105 detectors, the ratio (×100%) of AUEC values at ED for test vs. standard (90% CI) was 112.91% (105.55, 120.87), within the bioequivalence criteria of (80, 125). CONCLUSIONS: These studies supported the registration of reformulated mometasone cream in various markets.
[Mh] Termos MeSH primário: Furoato de Mometasona/administração & dosagem
Absorção Cutânea/efeitos dos fármacos
Vasoconstritores/química
Vasoconstritores/farmacologia
[Mh] Termos MeSH secundário: Administração Cutânea
Bioensaio
Seres Humanos
Furoato de Mometasona/química
Furoato de Mometasona/farmacologia
Projetos Piloto
Equivalência Terapêutica
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Vasoconstrictor Agents); 04201GDN4R (Mometasone Furoate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170913
[Lr] Data última revisão:
170913
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170310
[St] Status:MEDLINE
[do] DOI:10.1080/03639045.2017.1301949


  6 / 653 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28116488
[Au] Autor:Cirkovic I; Pavlovic B; Bozic DD; Jotic A; Bakic L; Milovanovic J
[Ad] Endereço:Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, Belgrade, 11000, Serbia. cirkoviciv@yahoo.com.
[Ti] Título:Antibiofilm effects of topical corticosteroids and intranasal saline in patients with chronic rhinosinusitis with nasal polyps depend on bacterial species and their biofilm-forming capacity.
[So] Source:Eur Arch Otorhinolaryngol;274(4):1897-1903, 2017 Apr.
[Is] ISSN:1434-4726
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Microbial biofilms have been implicated in the pathogenesis of chronic rhinosinusitis with nasal polyposis (CRSwNP). Intranasal application of corticosteroids and saline is a reliable option for their management. The aim of our study was to evaluate in vitro antibiofilm effects of corticosteroids and isotonic and hypertonic nasal saline in CRSwNP patients. The sinus mucosal specimens were harvested from the ethmoid cavity of 48 patients with CRSwNP and further subjected to hematoxylin-eosin staining and microbiology analysis. The biofilm-forming capacity of isolated bacterial strains was detected by microtiter-plate method and the effects of therapeutic doses of mometasone, fluticasone, isotonic and hypertonic saline on biofilm production were investigated. Bacterial strains were isolated in 42 (87.5%) patients: one organism in 34 (80.9%) and two organisms in 8 (19.1%). Staphylococcus epidermidis (34%) and Staphylococcus aureus (28%) were the most prevalent bacteria in biofilms of CRSwNP patients. Corticosteroids and saline solutions significantly reduced biofilm formation (p < 0.01 and p < 0.05, respectively) with better efficacy of fluticasone and isotonic nasal saline. Treatment with fluticasone, mometasone, isotonic and hypertonic nasal saline completely prevented biofilm production in 66, 50, 84 and 38% of bacterial strains, respectively. The most significant density reduction was observed in biofilm formed by Staphylococcus aureus, Pseudomonas aeruginosa and Streptococcus pneumoniae compared to other bacterial species (p < 0.01, p < 0.05, p < 0.05, respectively). The antibiofilm effects of corticosteroids and saline solutions also greatly depended on bacterial biomass (p < 0.05), with the most significant effect on high compared to small amount of formed biofilm. The topical steroids and nasal saline are shown to be potent antibiofilm agents in patients with CRSwNP. The effects of tested compounds depend on bacterial species and volume of formed biofilm.
[Mh] Termos MeSH primário: Corticosteroides/farmacologia
Biofilmes/efeitos dos fármacos
Pólipos Nasais/microbiologia
Rinite/microbiologia
Sinusite/microbiologia
Cloreto de Sódio/farmacologia
[Mh] Termos MeSH secundário: Administração Intranasal
Corticosteroides/uso terapêutico
Adulto
Idoso
Doença Crônica
Quimioterapia Combinada
Feminino
Fluticasona/farmacologia
Fluticasona/uso terapêutico
Seres Humanos
Técnicas In Vitro
Masculino
Meia-Idade
Furoato de Mometasona/farmacologia
Furoato de Mometasona/uso terapêutico
Pólipos Nasais/tratamento farmacológico
Estudos Prospectivos
Pseudomonas aeruginosa/efeitos dos fármacos
Pseudomonas aeruginosa/isolamento & purificação
Pseudomonas aeruginosa/fisiologia
Rinite/tratamento farmacológico
Sinusite/tratamento farmacológico
Cloreto de Sódio/uso terapêutico
Staphylococcus aureus/efeitos dos fármacos
Staphylococcus aureus/isolamento & purificação
Staphylococcus aureus/fisiologia
Staphylococcus epidermidis/efeitos dos fármacos
Staphylococcus epidermidis/isolamento & purificação
Staphylococcus epidermidis/fisiologia
Streptococcus pneumoniae/efeitos dos fármacos
Streptococcus pneumoniae/isolamento & purificação
Streptococcus pneumoniae/fisiologia
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 04201GDN4R (Mometasone Furoate); 451W47IQ8X (Sodium Chloride); CUT2W21N7U (Fluticasone)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170928
[Lr] Data última revisão:
170928
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170125
[St] Status:MEDLINE
[do] DOI:10.1007/s00405-017-4454-6


  7 / 653 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28108685
[Au] Autor:Mulhall AM; Zafar MA; Record S; Channell H; Panos RJ
[Ad] Endereço:Divison of Pulmonary, Critical Care, and Sleep Medicine, Cincinnati Veterans Affairs Medical Center and the Division of Pulmonary, Critical Care, and Sleep Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio. mulhalan@ucmail.uc.edu.
[Ti] Título:A Tablet-Based Multimedia Education Tool Improves Provider and Subject Knowledge of Inhaler Use Techniques.
[So] Source:Respir Care;62(2):163-171, 2017 Feb.
[Is] ISSN:1943-3654
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Although inhaled medications are effective therapies for COPD, many patients and providers use them incorrectly. METHODS: We recruited providers who prescribe inhalers or teach inhaler technique and assessed their use of metered-dose inhalers (MDIs), various dry powder inhalers (DPIs), and Respimat using predefined checklists. Then they watched tablet-based multimedia educational videos that demonstrated correct inhaler technique by a clinical pharmacist with teach-back from a patient and were re-evaluated. We also recruited patients with COPD and assessed their use of their prescribed inhalers and then retested them after 3-6 months. Baseline and follow-up respiratory symptoms were measured by the COPD Assessment Test. RESULTS: Fifty-eight providers and 50 subjects participated. For all providers, correct inhaler technique (reported as percentage correct steps) increased after the videos: MDI without a spacer (72% vs 97%) MDI with a spacer (72% vs 96%), formoterol DPI (50% vs 94%), mometasone DPI (43% vs 95%), tiotropium DPI (73% vs 99%), and Respimat (32% vs 93%) (before vs after, P < .001 for all comparisons). Subjects also improved their inhaler use technique after viewing the educational videos: MDI without a spacer (69% vs 92%), MDI with a spacer (73% vs 95%), and tiotropium DPI (83% vs 96%) (before vs after, P < .001 for all comparisons). The beneficial effect of this educational intervention declined slightly for subjects but was durably improved after several months. COPD Assessment Test scores did not demonstrate any change in respiratory symptoms. CONCLUSIONS: A tablet-based inhaler education tool improved inhaler technique for both providers and subjects. Although this intervention did show durable efficacy for improving inhaler use by patients, it did not reduce their respiratory symptoms.
[Mh] Termos MeSH primário: Computadores de Mão
Inaladores de Pó Seco
Tecnologia Educacional
Inaladores Dosimetrados
Educação de Pacientes como Assunto/métodos
[Mh] Termos MeSH secundário: Idoso
Combinação Albuterol e Ipratrópio/administração & dosagem
Antialérgicos/administração & dosagem
Broncodilatadores/administração & dosagem
Lista de Checagem
Educação Médica/métodos
Feminino
Seguimentos
Fumarato de Formoterol/administração & dosagem
Seres Humanos
Pneumopatias Obstrutivas/tratamento farmacológico
Masculino
Meia-Idade
Furoato de Mometasona/administração & dosagem
Multimídia
Médicos
Estudos Prospectivos
Avaliação de Sintomas
Brometo de Tiotrópio/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Albuterol, Ipratropium Drug Combination); 0 (Anti-Allergic Agents); 0 (Bronchodilator Agents); 04201GDN4R (Mometasone Furoate); W34SHF8J2K (Formoterol Fumarate); XX112XZP0J (Tiotropium Bromide)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170929
[Lr] Data última revisão:
170929
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170122
[St] Status:MEDLINE
[do] DOI:10.4187/respcare.05008


  8 / 653 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27913724
[Au] Autor:Bangiyev JN; Govil N; Sheyn A; Haupert M; Thottam PJ
[Ad] Endereço:Detroit Medical Center Department of Otolaryngology-HNS, Detroit, Michigan, USA.
[Ti] Título:Novel Application of Steroid Eluting Stents in Choanal Atresia Repair: A Case Series.
[So] Source:Ann Otol Rhinol Laryngol;126(1):79-82, 2017 Jan.
[Is] ISSN:1943-572X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To describe the application of mometasone furoate eluting sinus stent technology in the treatment of choanal atresia (CA) in the hopes of preventing postsurgical stenosis. METHODS: We analyzed 3 consecutive patients aged 4 days to 16 years undergoing repair of CA at a tertiary pediatric hospital. Mometasone furoate eluting sinus stents were placed intraoperatively. Postoperative need for revision surgery as well as routine surveillance endoscopy were used to determine success of surgery. RESULTS: Three patients of varying age and etiology underwent successful repair of choanal atresia/stenosis. The steroid eluting sinus stent was deployed successfully in all 3 cases. There was no identifiable restenosis in any of the 3 patients with 12-month follow-up. There were no complications noted throughout the follow-up period. CONCLUSIONS: Choanal atresia is a rare disorder that can prove difficult in postsurgical management. In our case series, mometasone furoate eluting stents were effective and safe for the management of this disease process. Further prospective studies are needed to determine the exact safety profile, long-term consequences, and efficacy of steroid eluting sinus stents in the pediatric population.
[Mh] Termos MeSH primário: Anti-Inflamatórios/administração & dosagem
Atresia das Cóanas/terapia
Stents Farmacológicos
Furoato de Mometasona/administração & dosagem
[Mh] Termos MeSH secundário: Adolescente
Pré-Escolar
Feminino
Seres Humanos
Recém-Nascido
Masculino
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 04201GDN4R (Mometasone Furoate)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170123
[Lr] Data última revisão:
170123
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161204
[St] Status:MEDLINE


  9 / 653 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27804089
[Au] Autor:Gupta AK; Versteeg SG
[Ad] Endereço:Department of Medicine, University of Toronto, Toronto, ON, Canada. publications@mediproberesearch.com.
[Ti] Título:Topical Treatment of Facial Seborrheic Dermatitis: A Systematic Review.
[So] Source:Am J Clin Dermatol;18(2):193-213, 2017 Apr.
[Is] ISSN:1179-1888
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Facial seborrheic dermatitis (SD), a chronic inflammatory skin condition, can impact quality of life, and relapses can be frequent. Three broad categories of agents are used to treat SD: antifungal agents, keratolytics, and corticosteroids. Topical therapies are the first line of defense in treating this condition. OBJECTIVE: Our objective was to critically review the published literature on topical treatments for facial SD. METHODS: We searched PubMed, Scopus, Clinicaltrials.gov, MEDLINE, Embase, and Cochrane library databases for original clinical studies evaluating topical treatments for SD. We then conducted both a critical analysis of the selected studies by grading the evidence and a qualitative comparison of results among and within studies. RESULTS: A total of 32 studies were eligible for inclusion, encompassing 18 topical treatments for facial SD. Pimecrolimus, the focus of seven of the 32 eligible studies, was the most commonly studied topical treatment. CONCLUSION: Promiseb , desonide, mometasone furoate, and pimecrolimus were found to be effective topical treatments for facial SD, as they had the lowest recurrence rate, highest clearance rate, and the lowest severity scores (e.g., erythema, scaling, and pruritus), respectively. Ciclopirox olamine, ketoconazole, lithium (gluconate and succinate), and tacrolimus are also strongly recommended (level A recommendations) topical treatments for facial SD, as they are consistently effective across high-quality trials (randomized controlled trials).
[Mh] Termos MeSH primário: Anti-Inflamatórios/uso terapêutico
Antifúngicos/uso terapêutico
Dermatite Seborreica/tratamento farmacológico
Fármacos Dermatológicos/uso terapêutico
Dermatoses Faciais/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Cutânea
Anti-Inflamatórios/efeitos adversos
Antifúngicos/administração & dosagem
Antifúngicos/efeitos adversos
Inibidores de Calcineurina/administração & dosagem
Inibidores de Calcineurina/efeitos adversos
Inibidores de Calcineurina/uso terapêutico
Dermatite Seborreica/microbiologia
Fármacos Dermatológicos/administração & dosagem
Fármacos Dermatológicos/efeitos adversos
Desonida/administração & dosagem
Desonida/efeitos adversos
Desonida/uso terapêutico
Dermatoses Faciais/microbiologia
Seres Humanos
Cetoconazol/administração & dosagem
Cetoconazol/efeitos adversos
Cetoconazol/uso terapêutico
Malassezia/efeitos dos fármacos
Furoato de Mometasona/administração & dosagem
Furoato de Mometasona/efeitos adversos
Furoato de Mometasona/uso terapêutico
Preparações de Plantas/administração & dosagem
Preparações de Plantas/efeitos adversos
Preparações de Plantas/uso terapêutico
Guias de Prática Clínica como Assunto
Piridonas/administração & dosagem
Piridonas/efeitos adversos
Piridonas/uso terapêutico
Qualidade de Vida
Ensaios Clínicos Controlados Aleatórios como Assunto
Tacrolimo/administração & dosagem
Tacrolimo/efeitos adversos
Tacrolimo/análogos & derivados
Tacrolimo/uso terapêutico
Resultado do Tratamento
Vitaminas/administração & dosagem
Vitaminas/efeitos adversos
Vitaminas/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Antifungal Agents); 0 (Calcineurin Inhibitors); 0 (Dermatologic Agents); 0 (Plant Preparations); 0 (Pyridones); 0 (Vitamins); 04201GDN4R (Mometasone Furoate); 19W019ZDRJ (ciclopirox); 7KYV510875 (pimecrolimus); J280872D1O (Desonide); R9400W927I (Ketoconazole); WM0HAQ4WNM (Tacrolimus)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170512
[Lr] Data última revisão:
170512
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161103
[St] Status:MEDLINE
[do] DOI:10.1007/s40257-016-0232-2


  10 / 653 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27740721
[Au] Autor:Amar NJ; Shekar T; Varnell TA; Mehta A; Philip G
[Ad] Endereço:Allergy & Asthma Research Institute, Waco, Texas.
[Ti] Título:Mometasone furoate (MF) improves lung function in pediatric asthma: A double-blind, randomized controlled dose-ranging trial of MF metered-dose inhaler.
[So] Source:Pediatr Pulmonol;52(3):310-318, 2017 Mar.
[Is] ISSN:1099-0496
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Mometasone furoate (MF), delivered via dry-powder inhaler (DPI) QD in the evening (PM), is a treatment option for pediatric patients with asthma. We evaluated MF delivered via a metered-dose inhaler (MDI), in children ages 5-11 years with persistent asthma. METHODS: This was a 12-week double-blind, double-dummy, placebo-controlled trial. Pateints were randomized to the following treatments: MF-MDI 50 mcg BID, MF-MDI 100 mcg BID, MF-MDI 200 mcg BID, MF-DPI 100 mcg QD PM, and placebo. The primary analysis assessed MF-MDI doses versus placebo, on the change in %-predicted forced expiratory volume in one second (FEV ) from baseline to week-12; a secondary analysis compared MF-MDI 50 mcg BID versus MF-DPI 100 mcg QD PM. Adverse events (AEs) were monitored throughout the trial. RESULTS: For change from baseline in %-predicted FEV at week 12, least-squares (LS) mean differences from placebo were 3.87 (P = 0.019), 6.29 (P < 0.001), and 5.34 (P = 0.001) percentage-points for MF-MDI 50, 100, and 200 mcg BID, respectively. The LS mean difference for MF-MDI 50 mcg BID versus MF-DPI 100 mcg QD PM was 1.39 (P = 0.368). AE incidences were similar among all treatment groups. There were no reports of oropharyngeal candidiasis or dysphonia, which were AEs pre-specified for analysis,. CONCLUSIONS: In children ages 5-11 years with persistent asthma, all three doses of MF-MDI (50, 100, and 200 mcg BID) demonstrated significant improvement in FEV after 12 weeks of treatment. MF was generally well tolerated with no new safety concerns identified in this trial. Pediatr Pulmonol. 2017;52:310-318. © 2016 Wiley Periodicals, Inc.
[Mh] Termos MeSH primário: Anti-Inflamatórios/administração & dosagem
Asma/tratamento farmacológico
Inaladores Dosimetrados
Furoato de Mometasona/administração & dosagem
[Mh] Termos MeSH secundário: Asma/fisiopatologia
Criança
Pré-Escolar
Relação Dose-Resposta a Droga
Método Duplo-Cego
Feminino
Volume Expiratório Forçado/fisiologia
Seres Humanos
Análise dos Mínimos Quadrados
Masculino
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 04201GDN4R (Mometasone Furoate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171011
[Lr] Data última revisão:
171011
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161015
[St] Status:MEDLINE
[do] DOI:10.1002/ppul.23563



página 1 de 66 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde